Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

J&J's Janssen Gets Europe OK for Twice-Yearly Schizophrenia Treatment

11/23/2021 | 07:03am EST

By Colin Kellaher

Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Tuesday said the European Commission approved the company's Byannli six-month maintenance treatment for schizophrenia in adults.

The drugmaker said the approval, which covers patients who are clinically stable on monthly or three-month doses, makes Byannli the first twice-yearly treatment of schizophrenia in adults in Europe.

The U.S. Food and Drug Administration in September approved a six-month version of the antipsychotic, marketed in the U.S. as Invega.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

11-23-21 0703ET

All news about JOHNSON & JOHNSON
08:53aMeiraGTx Gets $30 Million Milestone Payment From Janssen Pharmaceuticals
DJ
08:09aJOHNSON & JOHNSON : Marks More Than 2 Billion Doses of Medicine Donated to Date to Help Co..
PU
05:36aDA Davidson Lifts Johnson & Johnson's Price Target to $196 From $188, Citing 'Increased..
MT
01/26Galapagos Appoints Former Johnson & Johnson Exec to Succeed Retiring CEO
MT
01/26Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO
RE
01/26Raymond James Adjusts Johnson & Johnson's Price Target to $185 From $178, Keeps Outperf..
MT
01/26Genmab Announces Net Sales of DARZALEX for 2021
AQ
01/26COVID-19 Severity Appears Lower With Omicron, But High Hospitalization Volume Could Str..
MT
01/25What We're Reading This Week
AQ
01/25Nvidia, General Electric fall; IBM, American Express rise
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 304 M - -
Net income 2021 22 542 M - -
Net cash 2021 815 M - -
P/E ratio 2021 20,0x
Yield 2021 2,47%
Capitalization 443 B 443 B -
EV / Sales 2021 4,69x
EV / Sales 2022 4,32x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 168,38 $
Average target price 183,33 $
Spread / Average Target 8,88%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Alex Gorsky Executive Chairman
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
ELI LILLY AND COMPANY-13.89%215 642
NOVO NORDISK A/S-15.89%213 450